Data / Form D filings / Biolinq Inc
Biolinq Inc: Form D filings
Biolinq Inc, a biotechnology company in San Diego, CA, filed 12 Form D notices with the SEC between 2016 and 2025. The latest, on March 21, 2025, reports $90 million sold of a $100 million offering to 45 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 10260 SORRENTO VALLEY ROAD, San Diego, CA, 92121
- Phone
- (510) 847-9655
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1685406
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 21, 2025 | New notice | $100,000,000 | $90,000,000 | $10,000,000 | 45 | Mar 7, 2025 | sec.gov |
| Sep 13, 2024 | Amendment | $59,139,615 | $59,139,615 | 43 | Dec 13, 2023 | sec.gov | |
| Mar 26, 2024 | Amendment | $58,749,615 | $53,749,615 | $5,000,000 | 42 | Dec 13, 2023 | sec.gov |
| Dec 26, 2023 | New notice | $50,000,000 | $35,114,615 | $14,885,385 | 25 | Dec 13, 2023 | sec.gov |
| Jun 1, 2022 | Amendment | $105,609,392 | $77,946,902 | $27,662,490 | 62 | Sep 2, 2021 | sec.gov |
| Sep 17, 2021 | New notice | $109,511,762 | $62,178,431 | $47,333,331 | 54 | Sep 2, 2021 | sec.gov |
| Mar 23, 2021 | New notice | $6,000,000 | $5,223,811 | $776,189 | 21 | Mar 16, 2021 | sec.gov |
| Jul 7, 2020 | Amendment | $10,000,000 | $3,554,335 | $6,445,665 | 17 | Mar 25, 2020 | sec.gov |
| Apr 7, 2020 | New notice | $8,000,000 | $3,554,335 | $4,445,665 | 17 | Mar 25, 2020 | sec.gov |
| Mar 20, 2019 | New notice | $3,000,000 | $3,000,000 | 9 | Mar 13, 2019 | sec.gov | |
| Nov 27, 2017 | New notice | $13,115,919 | $8,115,919 | $5,000,000 | 17 | Nov 14, 2017 | sec.gov |
| Sep 28, 2016 | New notice | $750,000 | $450,000 | $300,000 | 5 | Sep 16, 2016 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| CHRIS DIMITROPOULOS | Director | |
| DAVID AFFAS BERRY | Director | |
| DEREK RAPP | Director | |
| ZINA AFFAS BESSE | Director | |
| RICHARD YANG | Executive Officer, Director | |
| THAD JOHNSON | Director | |
| JARED AFFAS TANGNEY | Executive Officer | |
| DAN BRADBURY | Director | |
| DAVID AFFAS ARIDA | Executive Officer |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Mar 17, 2025 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Biolinq Inc reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.